FDA Approves New Indication for Keytruda

The Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Keytruda (pembrolizumab) for the treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose disease has progressed after other treatments and with tumors that express PD-L1.

Study Raises Concerns Over Narcotic Use in Older COPD Patients

A new study is raising safety concerns about the high rate of new opioid use among older adults with chronic obstructive pulmonary disease (COPD).

Benefits of Psychological Tx for Depression May Be Overstated

The benefits of psychological therapy for depression are overstated, according to research published in PLOS ONE.

CPAP Could Ease Depression in OSA Patients

Patients with obstructive sleep apnea (OSA) are at increased risk for depression, but continuous positive airway pressure (CPAP) therapy may ease their depression symptoms.

Height May Impact Risk of Premature Death for Dialysis Patients

Tall stature may be linked with an increased risk for premature death in kidney failure patients on dialysis.

Can Height Predict Cancer Risk?

A study of more than five million Swedish men and women suggests that greater height may mean greater risk of cancer.

Serotonin Levels Low in Ankylosing Spondylitis

Patients with ankylosing spondylitis (AS) have lower serotonin levels than healthy controls and patients with rheumatoid arthritis (RA).

Increased BMI Protective Against Blood Transfusions

For patients undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA), increased body mass index (BMI) is protective against blood transfusions.

Habit Reversal Beneficial in Atopic Dermatitis

Habit reversal (HR) seems to be beneficial for reducing scratching among patients with atopic dermatitis (AD), according to a review published in the British Journal of Dermatology.

Add-On Sitagliptin vs. Sulphonylurea Compared on Insulin Initiation Risk

For patients with type 2 diabetes mellitus (T2DM) treated with metformin, add-on sitagliptin is associated with a lower risk of insulin initiation than add-on sulphonylurea.